Skip to main content

Rheumatoid arthritis

Clinical trials

12-07-2022 | Rheumatoid arthritis | News

Background methotrexate may boost placebo response in RA trials

Background therapy with methotrexate may partly explain placebo responses observed in rheumatoid arthritis clinical trials, study findings indicate.

Rituximab and rheumatology practice in the COVID-19 era

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

Anifrolumab for the treatment of lupus

Anifrolumab for the treatment of SLE

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

18-08-2021 | Rheumatoid arthritis | News

EULAR issues guidance for RA prevention trials

A EULAR taskforce has developed guidance on how to conduct clinical trials involving people at risk for rheumatoid arthritis.

New additions to the Adis Journal Club

Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

JAK inhibitor safety

Data summary, expert discussion, & research news on the potential risks associated with JAK inhibitors.

ACR Convergence 2021 highlights

ACR Convergence 2021

3–9 November: Keep up with the latest news and interviews from the conference.

Febuxostat and cardiovascular risk in people with gout

Febuxostat and cardiovascular risk in people with gout

How will the FAST trial results impact regulatory guidance & clinical practice?

Telemedicine in rheumatology

Telemedicine in rheumatology: COVID-19 and beyond

Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.

Get ready for ACR Convergence 2020

ACR Convergence 2020

5 – 9 November: Preview the conference with session recommendations and updates on upcoming coverage.

05-10-2020 | Rheumatoid arthritis | News

Placebo responses in RA trials are more than just a psychologic effect

The placebo response among patients with rheumatoid arthritis participating in clinical trials is not only a subjective phenomenon, it is also evident in biochemical data, study findings indicate.

Rheumatoid arthritis medication

27-04-2020 | Rheumatoid arthritis | Highlight | News

Phase 2 RA trials ‘systematically overestimate’ treatment efficacy

The reported efficacy of treatments for rheumatoid arthritis is consistently higher in phase 2 than phase 3 randomized controlled trials, mainly due to differences in inclusion criteria, say the authors of a systematic review and meta-analysis.

Phase 2 RA trials ‘systematically overestimate’ treatment efficacy

Phase 2 RA trials ‘systematically overestimate’ treatment efficacy

The reported efficacy of treatments for rheumatoid arthritis is consistently higher in phase 2 than phase 3 randomized controlled trials, mainly due to differences in inclusion criteria, say the authors of a systematic review and meta-analysis.

20-10-2018 | Rheumatoid arthritis | Article

On-drug and drug-free remission by baseline symptom duration: Abatacept with methotrexate in patients with early rheumatoid arthritis

Bykerk VP et al. Rheumatol Int 2018; 38: 2225–2231. doi: 10.1007/s00296-018-4173-3

17-08-2018 | Rheumatoid arthritis | Article

Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: A randomized, phase III, non-inferiority study

Tanaka Y et al. Rheumatology (Oxford) 2018: key250. doi: 10.1093/rheumatology/key250

Clinical, ultrasound, and predictability outcomes following certolizumab pegol treatment (with methotrexate) in patients with moderate-to-severe rheumatoid arthritis: 52-week results from the CZP-SPEED study

Clinical, ultrasound, and predictability outcomes following certolizumab pegol treatment (with methotrexate) in patients with moderate-to-severe rheumatoid arthritis: 52-week results from the CZP-SPEED study

The aim of this trial was to assess the impact of certolizumab pegol treatment on clinical, patient-reported, and musculoskeletal ultrasound outcomes in Italian patients with rheumatoid arthritis [read more].
Sarzi-Puttini P et al. Adv Ther 2018. doi: 10.1007/s12325-018-0751-8